Shaman
This article was originally published in The Tan Sheet
Executive Summary
San Francisco company switches focus from pharmaceuticals to botanicals, which Shaman believes offer better "near-term potential" for reaching the market. The company decided to close its pharmaceutical operations after FDA informed it that more clinical data would be required in an NDA for the antidiarrheal Provir. Shaman will seek shareholder approval to shift assets into its privately held subsidiary, Shaman Botanicals, and may spin off Botanicals as a separate public company. Shaman Botanicals currently is led by interim CEO Loren Israelsen ("The Tan Sheet" Feb. 1, In Brief). Shaman Pharmaceuticals CEO Lisa Conte will become president and chief operating officer of Botanicals
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning